Adding Aprepitant to Palonosetron Does Not Decrease Carboplatin-induced Nausea and Vomiting in Patients with Gynecologic Cancer

Overview

Journal J Pharm Health Care Sci

Publisher Biomed Central

Specialty Pharmacology

Date 2021 Jun 1

PMID 34059157

Citations 1

Authors

Yuko Watanabe

Yoshitaka Saito

Takashi Mitamura

Yoh Takekuma

Mitsuru Sugawara

Affiliations

Soon will be listed here.

Abstract

Background: Recently, aprepitant has been recommended in carboplatin-based regimens, but there are limited reports on the efficacy of administering aprepitant, palonosetron, and dexamethasone (DEX) in carboplatin-containing regimens. Moreover, because aprepitant is an expensive drug, confirming its effectiveness is very important from the medical cost perspective. In this study, we examined the efficacy of prophylactically administered aprepitant, palonosetron and DEX, in paclitaxel and carboplatin (TC) combination chemotherapy.

Methods: Patients with gynecologic cancer who were treated with paclitaxel (175 mg/m) and carboplatin (area under the curve, AUC = 5-6) combination chemotherapy were retrospectively evaluated. The complete response (CR) rate, severity of nausea, and incidence of anorexia in the first course were compared between patients who did not receive aprepitant (control group) and those who received (aprepitant group).

Results: The 106 patients were divided into two groups, consisting of 52 and 54 the control and aprepitant groups, respectively, and the patient background showed no significant difference between both groups. The CR rate of the overall phase between the control and aprepitant groups was 73.1 vs. 74.1%, that in the acute phase was 98.1 vs. 100%, and in the delayed phase was 75.0 vs. 74.1%, respectively, without any significant difference. The severity of nausea and incidence of anorexia were also not significantly different between both groups.

Conclusions: The results of the study suggest that adding aprepitant to palonosetron and DEX does not prevent carboplatin-induced nausea and vomiting in gynecologic cancer patients. Therefore, adding aprepitant to palonosetron does not decrease carboplatin-induced nausea and vomiting in patients with gynecologic cancer.

Citing Articles

Multi-institutional survey of antiemetic therapy in lung cancer patients treated with carboplatin in Hokushin region.

Ide T, Nishino Y, Takiguchi T, Kanda S, Otsuki K, Hayashi R BMC Pulm Med. 2023; 23(1):228.

PMID: 37365528 PMC: 10294304. DOI: 10.1186/s12890-023-02524-2.

References

Kitagawa R, Katsumata N, Shibata T, Kamura T, Kasamatsu T, Nakanishi T . Paclitaxel Plus Carboplatin Versus Paclitaxel Plus Cisplatin in Metastatic or Recurrent Cervical Cancer: The Open-Label Randomized Phase III Trial JCOG0505. J Clin Oncol. 2015; 33(19):2129-35. DOI: 10.1200/JCO.2014.58.4391. View

Sakamoto T, Saito Y, Kobayashi M, Yamada T, Takekuma Y, Nakai M . Effect of palonosetron and dexamethasone administration on the prevention of gastrointestinal symptoms in hepatic arterial chemoembolization with epirubicin. Support Care Cancer. 2019; 28(7):3251-3257. DOI: 10.1007/s00520-019-05178-1. View

Sugimori Y, Ota T, Ujihira T, Ishiguro T, Ogishima D . A phase II randomised study to evaluate the efficacy of aprepitant plus palonosetron for preventing delayed-phase CINV associated with TC therapy in gynaecological cancer. J Obstet Gynaecol Res. 2017; 43(9):1454-1459. DOI: 10.1111/jog.13378. View

Komatsu Y, Okita K, Yuki S, Furuhata T, Fukushima H, Masuko H . Open-label, randomized, comparative, phase III study on effects of reducing steroid use in combination with Palonosetron. Cancer Sci. 2015; 106(7):891-5. PMC: 4520641. DOI: 10.1111/cas.12675. View

Iihara H, Ishihara M, Fujii H, Yoshimi C, Yamada M, Suzuki A . Comparison of the Control of Nausea and Vomiting among Several Moderately Emetic-Risk Chemotherapy Regimens. J Cancer. 2016; 7(5):569-75. PMC: 4820733. DOI: 10.7150/jca.13637. View

Kusagaya H, Inui N, Karayama M, Fujisawa T, Enomoto N, Kuroishi S . Evaluation of palonosetron and dexamethasone with or without aprepitant to prevent carboplatin-induced nausea and vomiting in patients with advanced non-small-cell lung cancer. Lung Cancer. 2016; 90(3):410-6. DOI: 10.1016/j.lungcan.2015.11.009. View

Yahata H, Kobayashi H, Sonoda K, Shimokawa M, Ohgami T, Saito T . Efficacy of aprepitant for the prevention of chemotherapy-induced nausea and vomiting with a moderately emetogenic chemotherapy regimen: a multicenter, placebo-controlled, double-blind, randomized study in patients with gynecologic cancer receiving.... Int J Clin Oncol. 2015; 21(3):491-7. DOI: 10.1007/s10147-015-0928-y. View

McCrea J, Majumdar A, Goldberg M, Iwamoto M, Gargano C, Panebianco D . Effects of the neurokinin1 receptor antagonist aprepitant on the pharmacokinetics of dexamethasone and methylprednisolone. Clin Pharmacol Ther. 2003; 74(1):17-24. DOI: 10.1016/S0009-9236(03)00066-3. View

Suzuki K, Yamanaka T, Hashimoto H, Shimada Y, Arata K, Matsui R . Randomized, double-blind, phase III trial of palonosetron versus granisetron in the triplet regimen for preventing chemotherapy-induced nausea and vomiting after highly emetogenic chemotherapy: TRIPLE study. Ann Oncol. 2016; 27(8):1601-6. DOI: 10.1093/annonc/mdw220. View

10.

Lundberg J, Crawford B, Phillips G, Berger M, Wesolowski R . Incidence of infusion-site reactions associated with peripheral intravenous administration of fosaprepitant. Support Care Cancer. 2014; 22(6):1461-6. PMC: 4277851. DOI: 10.1007/s00520-013-2106-y. View

11.

Roila F, Molassiotis A, Herrstedt J, Aapro M, Gralla R, Bruera E . 2016 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients. Ann Oncol. 2016; 27(suppl 5):v119-v133. DOI: 10.1093/annonc/mdw270. View

12.

Aogi K, Takeuchi H, Saeki T, Aiba K, Tamura K, Iino K . Optimizing antiemetic treatment for chemotherapy-induced nausea and vomiting in Japan: Update summary of the 2015 Japan Society of Clinical Oncology Clinical Practice Guidelines for Antiemesis. Int J Clin Oncol. 2020; 26(1):1-17. PMC: 7788035. DOI: 10.1007/s10147-020-01818-3. View

13.

Yoshida N, Taguchi T, Nakanishi M, Inoue K, Okayama T, Ishikawa T . Efficacy of the combination use of aprepitant and palonosetron for improving nausea in various moderately emetogenic chemotherapy regimens. BMC Pharmacol Toxicol. 2019; 20(1):6. PMC: 6332848. DOI: 10.1186/s40360-018-0278-2. View

14.

Yokoe T, Hayashida T, Nagayama A, Nakashoji A, Maeda H, Seki T . Effectiveness of Antiemetic Regimens for Highly Emetogenic Chemotherapy-Induced Nausea and Vomiting: A Systematic Review and Network Meta-Analysis. Oncologist. 2018; 24(6):e347-e357. PMC: 6656484. DOI: 10.1634/theoncologist.2018-0140. View

15.

Berger M, Ettinger D, Aston J, Barbour S, Bergsbaken J, Bierman P . NCCN Guidelines Insights: Antiemesis, Version 2.2017. J Natl Compr Canc Netw. 2017; 15(7):883-893. DOI: 10.6004/jnccn.2017.0117. View

16.

Depre M, Van Hecken A, Oeyen M, De Lepeleire I, Laethem T, Rothenberg P . Effect of aprepitant on the pharmacokinetics and pharmacodynamics of warfarin. Eur J Clin Pharmacol. 2005; 61(5-6):341-6. DOI: 10.1007/s00228-005-0907-8. View

17.

Tsukiyama I, Hasegawa S, Ikeda Y, Takeuchi M, Tsukiyama S, Kurose Y . Cost-effectiveness of aprepitant in Japanese patients treated with cisplatin-containing highly emetogenic chemotherapy. Cancer Sci. 2018; 109(9):2881-2888. PMC: 6125450. DOI: 10.1111/cas.13736. View

18.

Lorusso D, Petrelli F, Coinu A, Raspagliesi F, Barni S . A systematic review comparing cisplatin and carboplatin plus paclitaxel-based chemotherapy for recurrent or metastatic cervical cancer. Gynecol Oncol. 2014; 133(1):117-23. DOI: 10.1016/j.ygyno.2014.01.042. View

19.

du Bois A, Luck H, Meier W, Adams H, Mobus V, Costa S . A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. J Natl Cancer Inst. 2003; 95(17):1320-9. DOI: 10.1093/jnci/djg036. View

20.

Hesketh P, Kris M, Basch E, Bohlke K, Barbour S, Clark-Snow R . Antiemetics: American Society of Clinical Oncology Clinical Practice Guideline Update. J Clin Oncol. 2017; 35(28):3240-3261. DOI: 10.1200/JCO.2017.74.4789. View